Application of a MCDA-based model to support and streamline policy and clinical decision-making in Canada for growth hormone (GH) therapy for Prader-Willi syndrome (PWS), a rare genetic disorder with serious long-term consequences including short stature and morbid obesity. This evidence concerns the gene GH1 and hereditary disease.